Adial Pharmaceuticals (ADIL) Competitors $0.71 -0.01 (-2.02%) Closing price 04:00 PM EasternExtended Trading$0.70 -0.01 (-1.24%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADIL vs. VOR, FNCH, SLGL, OVID, QTTB, LGVN, NAII, CGTX, DRRX, and ELEVShould you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include Vor Biopharma (VOR), Finch Therapeutics Group (FNCH), Sol-Gel Technologies (SLGL), Ovid Therapeutics (OVID), Q32 Bio (QTTB), Longeveron (LGVN), Natural Alternatives International (NAII), Cognition Therapeutics (CGTX), DURECT (DRRX), and Elevation Oncology (ELEV). These companies are all part of the "pharmaceutical products" industry. Adial Pharmaceuticals vs. Vor Biopharma Finch Therapeutics Group Sol-Gel Technologies Ovid Therapeutics Q32 Bio Longeveron Natural Alternatives International Cognition Therapeutics DURECT Elevation Oncology Vor Biopharma (NYSE:VOR) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership. Do analysts recommend VOR or ADIL? Vor Biopharma currently has a consensus price target of $7.06, suggesting a potential upside of 3,762.69%. Adial Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 1,023.91%. Given Vor Biopharma's higher possible upside, analysts plainly believe Vor Biopharma is more favorable than Adial Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vor Biopharma 0 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.40Adial Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media refer more to VOR or ADIL? In the previous week, Adial Pharmaceuticals had 7 more articles in the media than Vor Biopharma. MarketBeat recorded 8 mentions for Adial Pharmaceuticals and 1 mentions for Vor Biopharma. Adial Pharmaceuticals' average media sentiment score of 0.67 beat Vor Biopharma's score of 0.47 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in VOR or ADIL? Adial Pharmaceuticals received 54 more outperform votes than Vor Biopharma when rated by MarketBeat users. However, 65.88% of users gave Vor Biopharma an outperform vote while only 58.51% of users gave Adial Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVor BiopharmaOutperform Votes5665.88% Underperform Votes2934.12% Adial PharmaceuticalsOutperform Votes11058.51% Underperform Votes7841.49% Is VOR or ADIL more profitable? Vor Biopharma's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vor BiopharmaN/A N/A N/A Adial Pharmaceuticals N/A -168.25%-148.46% Do insiders & institutionals believe in VOR or ADIL? 97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 2.9% of Vor Biopharma shares are owned by insiders. Comparatively, 5.2% of Adial Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, VOR or ADIL? Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVor BiopharmaN/AN/AN/A-$1.51-0.12Adial PharmaceuticalsN/AN/A-$5.12M-$1.46-0.49 Which has more risk and volatility, VOR or ADIL? Vor Biopharma has a beta of -0.21, meaning that its stock price is 121% less volatile than the S&P 500. Comparatively, Adial Pharmaceuticals has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. SummaryAdial Pharmaceuticals beats Vor Biopharma on 8 of the 15 factors compared between the two stocks. Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADIL vs. The Competition Export to ExcelMetricAdial PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.62M$6.52B$5.37B$8.38BDividend YieldN/A2.65%5.22%4.11%P/E Ratio-0.498.9226.8419.71Price / SalesN/A253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book0.296.466.794.50Net Income-$5.12M$143.98M$3.23B$248.18M7 Day Performance9.51%3.04%4.07%1.14%1 Month Performance9.51%7.44%12.52%15.20%1 Year Performance-49.16%-2.46%16.83%6.56% Adial Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADILAdial Pharmaceuticals3.2886 of 5 stars$0.71-2.0%$8.00+1,023.9%-51.6%$5.62MN/A-0.4920Earnings ReportAnalyst RevisionVORVor Biopharma2.7944 of 5 stars$0.18-0.8%$7.06+3,921.2%-89.7%$21.91MN/A-0.11140High Trading VolumeFNCHFinch Therapeutics GroupN/A$13.48+1.7%N/A+507.1%$21.65M$110,000.00-1.53190SLGLSol-Gel Technologies2.1765 of 5 stars$7.72+3.3%$50.00+547.7%+10.6%$21.51M$11.54M-22.7150Gap UpOVIDOvid Therapeutics4.1712 of 5 stars$0.30-0.6%$3.03+907.4%-90.8%$21.41M$548,000.00-0.6460Analyst RevisionGap UpQTTBQ32 Bio2.12 of 5 stars$1.74-1.7%$24.71+1,320.4%-94.1%$21.23M$-6,651,000.00-0.1239Gap DownLGVNLongeveron2.8115 of 5 stars$1.40-1.4%$8.67+519.0%+8.5%$20.90M$2.23M-0.2220News CoverageAnalyst RevisionNAIINatural Alternatives International0.7244 of 5 stars$3.31+1.8%N/A-50.0%$20.52M$121.85M-2.57290News CoverageEarnings ReportAnalyst ForecastCGTXCognition Therapeutics2.5538 of 5 stars$0.33+1.5%$6.13+1,756.1%-83.9%$20.46MN/A-0.3420DRRXDURECT0.1765 of 5 stars$0.65+3.1%N/A-41.3%$20.17M$2.03M-1.0780Gap DownHigh Trading VolumeELEVElevation Oncology2.9143 of 5 stars$0.34+20.4%$3.39+895.8%-91.2%$20.14MN/A-0.4140Negative NewsEarnings ReportGap Down Related Companies and Tools Related Companies Vor Biopharma Alternatives Finch Therapeutics Group Alternatives Sol-Gel Technologies Alternatives Ovid Therapeutics Alternatives Q32 Bio Alternatives Longeveron Alternatives Natural Alternatives International Alternatives Cognition Therapeutics Alternatives DURECT Alternatives Elevation Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADIL) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADIL Stock Free ADIL Stock Alerts